Skip to content
★ Sign in to follow
KC

Kevin Church

Vice-Président de la Découverte
Total declarations
34
Company
1
▲ Purchases (0 ops.)
—
▼ Sales (8 ops.)
€39k

Latest filing published 05 Mar 2026 for LeonaBio, Inc..

Insider track record

Disclosed buys
0
Disclosed sells
8

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Kevin Church: trading record in brief

All filings by Kevin Church on record concern LeonaBio, Inc., in the capacity of senior executive. Between 18 May 2021 and 4 March 2026, the trades on record add up to 34 filings.

Every open-market trade on record is a sale: 8 sales worth €39k. The rest of the record consists of 16 share grants and 10 option exercises. Since January 2026: no purchases and 2 sales on the market.

On 5 March 2026 came the latest disclosure, an open-market sale for €6,285 in LeonaBio, Inc. Typically, a trade is published a median of 5 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Kevin Church

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations16 total
  • ◇
    CHIEF SCIENTIFIC OFFICERExecutivesLeonaBio, Inc.
    0SEC
    5,856 shares0Common StockSEC:0001822499-26-000004:0
  • ◆
    CHIEF SCIENTIFIC OFFICERExecutivesAthira Pharma, Inc.
    2,310 USD11SEC
    1,000 shares@ US$2.314.5% of flowCommon StockSEC:0001822499-26-000002:0
  • ◆
    CHIEF SCIENTIFIC OFFICERExecutivesAthira Pharma, Inc.
    2,312 USD11SEC
    10,000 shares@ US$0.23124.8% of flowCommon StockSEC:0001415889-25-019070:0
  • ◆
    CHIEF SCIENTIFIC OFFICERExecutivesAthira Pharma, Inc.
    5,456 USD12SEC
    9,920 shares@ US$0.5510.4% of flowCommon StockSEC:0001415889-25-000534:0
  • ◆
    CHIEF SCIENTIFIC OFFICERExecutivesAthira Pharma, Inc.
    6,637 USD12SEC
    4,953 shares@ US$1.3412.3% of flowCommon StockSEC:0001415889-24-022985:0
  • ◆
    CHIEF SCIENTIFIC OFFICERExecutivesAthira Pharma, Inc.
    1,950 USD0SEC
    809 shares@ US$2.413.6% of flowCommon StockSEC:0001415889-24-004146:0
  • ◆
    Chief Scientific OfficerExecutivesAthira Pharma, Inc.
    1,950 USD11SEC
    809 shares@ US$2.413.6% of flowCommon StockSEC:0001209191-24-001142:0
  • ◇
    Chief Scientific OfficerExecutivesAthira Pharma, Inc.
    8,654 USD13SEC
    6,410 shares@ US$1.3516.0% of flowCommon StockSEC:0001209191-23-021248:0
  • ◆
    Executive VP, ResearchExecutivesAthira Pharma, Inc.
    1,800 USD11SEC
    657 shares@ US$2.743.5% of flowCommon StockSEC:0001209191-23-004468:0
  • ◇
    Executive VP, ResearchExecutivesAthira Pharma, Inc.
    4,995 USD12SEC
    3,700 shares@ US$1.3510.1% of flowCommon StockSEC:0001209191-22-054950:0
  • ◆
    Executive VP, ResearchExecutivesAthira Pharma, Inc.
    0SEC
    10,000 shares0Common StockSEC:0001209191-22-039336:0
  • ◆
    Executive VP, ResearchExecutivesAthira Pharma, Inc.
    1,716 USD12SEC
    243 shares@ US$7.068.1% of flowCommon StockSEC:0001209191-22-036067:0
  • ◇
    Executive VP, ResearchExecutivesAthira Pharma, Inc.
    3,751 USD12SEC
    3,152 shares@ US$1.197.7% of flowCommon StockSEC:0001209191-22-011485:0
  • ◆
    Executive VP, ResearchExecutivesAthira Pharma, Inc.
    1,201 USD11SEC
    96 shares@ US$12.512.5% of flowCommon StockSEC:0001209191-22-004118:0
  • ◆
    Vice President of DiscoveryExecutivesAthira Pharma, Inc.
    2,673 USD12SEC
    185 shares@ US$14.455.1% of flowCommon StockSEC:0001209191-21-039625:0
  • ◇
    Vice President of DiscoveryExecutivesAthira Pharma, Inc.
    3,278 USD12SEC
    3,152 shares@ US$1.046.3% of flowCommon StockSEC:0001209191-21-039242:0

16 of 16 declarations